Xuesong Li

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 9

Top Topics

Replacement Therapy

Top Venues

Clinical case reports

Cancer innovation

This page only lists publications with an associated author ORCID identifier.

Publications

Xuesong Li, Chenxiang Cao
Levothyroxine sodium tablets reversed Hashimoto thyroiditis-induced kidney injury, muscle injury, and lipid metabolism disorder: A case report and literature review. Medicine 103 (32) (2024)
Xuesong Li, Liangbiao Gu, Wenhui Zhao, Zhuo Yu, Jianzhong Xiao, Chenxiang Cao
Successful management of a multiple endocrine neoplasia type 1-associated thymic neuroendocrine neoplasms with acute chest pain as initial symptom: A rare case report. Clinical case reports 12 (6) (2024)
Xuesong Li, Zhuo Yu
Role of liquid-liquid phase separation in cancer: Mechanisms and therapeutic implications. Cancer innovation 3 (5) (2024)
Xuesong Li, Liangbiao Gu, Wenhui Zhao, Jianzhong Xiao, Chenxiang Cao
Primary hyperaldosteronism associated with type 3 autoimmune polyendocrine syndrome: A rare case report. Clinical case reports 12 (8) (2024)
Xuesong Li, Chenxiang Cao
Levothyroxine sodium tablets reversed Hashimoto thyroiditis-induced kidney injury, muscle injury, and lipid metabolism disorder: A case report and literature review. Medicine 103 (32) (2024)
Xuesong Li, Liangbiao Gu, Wenhui Zhao, Zhuo Yu, Jianzhong Xiao, Chenxiang Cao
Successful management of a multiple endocrine neoplasia type 1-associated thymic neuroendocrine neoplasms with acute chest pain as initial symptom: A rare case report. Clinical case reports 12 (6) (2024)
Xuesong Li, Liangbiao Gu, Wenhui Zhao, Jianzhong Xiao, Chenxiang Cao
Primary hyperaldosteronism associated with type 3 autoimmune polyendocrine syndrome: A rare case report. Clinical case reports 12 (8) (2024)
Xuesong Li, Zheng Mo, Zhuo Yu
Comprehensive treatment of von Hippel-Lindau disease: A case report. Cancer innovation 3 (2) (2023)
Xuesong Li, Zheng Mo, Zhuo Yu
Comprehensive treatment of von Hippel-Lindau disease: A case report. Cancer innovation 3 (2) (2023)